Login
$HUMA
$0.53 -$0.03 (4.66%) Live

Company Executives

Officer Age In this role 2025 pay Source
Laura E. Niklason Also a director
President, Chief Executive Officer and Director
63 Not stated $5,234,908
Dale A. Sander
CFO and Chief Corp. Dev. Off
Title from the Form 4 dated May 18, 2026
66 Not stated $2,131,658
Shamik J. Parikh
Chief Medical Officer
53 Since 2022
4 years
$2,096,556

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 28, 2026 · updated by the 8-K of Sep 28, 2026

Directors
14
serving now
Independent
8 of 10
stated in the proxy; 4 not stated
Average tenure
4.3 years
from year joined
CEO also chairs the board
No
Kathleen Sebelius
Director Age On board Independent Committees Other public boards 2025 pay Source
Kathleen Sebelius
77 2021
5 years
Independent
Audit Committee
Devoted Health, Inc., Included Health Inc., Exact Sciences Corporation $227,800
Laura E. Niklason
63 2021
5 years
Not independent None stated None stated Paid as CEO
John P. Bamforth
62 2024
2 years
Independent
Commercial Committee
None stated $202,800
Keith Anthony Jones
65 2024
2 years
Independent None stated None stated $202,800
Emery N. Brown
69 2021
5 years
Independent
Nominating and Governance Committee
None stated $202,800
Michael T. Constantino
63 2021
5 years
Independent
Audit Committee · Chair
None stated $210,300
Brady W. Dougan
66 2021
5 years
Not independent None stated None stated $202,800
C. Bruce Green
70 2022
4 years
Independent
Nominating and Governance Committee
None stated $202,800
Diane Seimetz
55 2022
4 years
Independent None stated Cumulus Oncology, GlycanAGE, Temedica, mbiomics $202,800
Max Wallace
74 2021
5 years
Not stated
Nominating and Governance Committee · Chair
None stated $207,800
Susan Windham-Bannister
74 2021
5 years
Not stated
Commercial Committee · Chair
Aridis Pharmaceuticals, Inc. $207,800
Scott Coward Joined Sep 22, 2026
- - -
Audit Committee
- -
Paul Kuznik Joined Sep 22, 2026
- - -
Commercial Committee
- -
Todd M. Pope Leaving at the meeting
60 2021
5 years
Independent
Compensation Committee · Chair
None stated $207,800

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

6 disclosed in the proxy filed Apr 28, 2026
directors and executive officers
Amount not stated

Customary indemnification agreements with the directors and executive officers of Humacyte following the Merger.

With Humacyte Open in proxy
Frenova Renal Research
subsidiary of Fresenius Medical Care
Approximately $350,000
2023

Services agreements (May 2022 and June 2023) for a study of outcomes of dialysis patients; company paid for clinical research services performed under them.

Frenova Renal Research
Approximately $24,000 and $173,000
2024 and 2025

Master services agreement (June 2024) under which Frenova performs clinical research services for the V012 Phase 3 clinical trial.

Fresenius Medical Care Deutschland GmbH
Approximately $320,000
2023

Service agreement (July 2024) under which Frenova conducts a study of hemodialysis patient data in certain European countries; company paid for services in 2023.

Fresenius Medical Care
Amount not stated

Distribution agreement (June 2018, as amended) giving Fresenius Medical Care a right to receive a royalty on sales of the ATEV distribution product.

With Legacy Humacyte Open in proxy
Yale University
Amount not stated

Three license agreements, two still in effect; Legacy Humacyte has made payments of license fees and other expenses to Yale.

With Legacy Humacyte Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support